
SURROGATE ENDPOINTS CREATE POTENTIAL, REQUIRE STATISTICAL VALIDATION
Nov 06, 2019
Posted by IDDI Inc

USING DISEASE FREE SURVIVAL (DFS) AS A PRIMARY ENDPOINT IN EARLY BREAST CANCER
Nov 06, 2019
Posted by IDDI Inc





BeiGene and Amgen Announced a Global Strategic Oncology Collaboration
Nov 01, 2019
Posted by BeiGene
